An International Multicenter Randomized Open-Label Comparative Study of the Efficacy and Safety of BCD-131 (JSC BIOCAD, Russia) and Mircera (F. Hoffmann-La Roche Ltd, Switzerland) in Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis
Phase of Trial: Phase II
Latest Information Update: 29 Jul 2019
Price : $35 *
At a glance
- Drugs BCD 131 (Primary) ; Methoxy polyethylene glycol-epoetin beta
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Biocad
- 29 May 2019 Status changed from active, no longer recruiting to completed.
- 13 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 10 May 2018 New trial record